COMPANY

Primrose Bio

HQ: San Diego, CA source · primrosebio.com ↗ · West Coast

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

9NIH grants

Funding and NIH signals

NIH award NIH awarded $952K (SBIR Phase II 1R44TR006096-01, new, notice Jul 8, 2026). NIH RePORTER 1R44TR006096-01 (Jul 8, 2026)
Evidence (1 event)
- Jul 8, 2026 · NIH RePORTER 1R44TR006096-01
  Organization: PRIMROSE BIO, INC.; City/State: SAN DIEGO, CA; Project number: 1R44TR006096-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 951630; Administering IC: National Center for Advancing Translational Sciences; Project title: Enhanced nucleic acid therapeutics: synthetic sequence elements for boosting protein expression in genetic medicines; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raise Growth · amount not disclosed · announced Sep 22, 2026 Company release ↗
Source quote
- Sep 22, 2026 · Company release ↗
  “Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Sep 22, 2026 Raise Growth · amount not disclosed source ↗
Jul 15, 2026 Grant Government grant announced Jul 15, 2026. Source: company's own press page. source ↗

Funding

Last 2 years.

Jul 15, 2026 Government grant announced Jul 15, 2026. Source: company's own press page. source ↗

NIH awards 9

Annual award amounts. Total $5.5M.

Jul 8, 2026 NIH award 1R44TR006096-01 FY2026: $951,630 awarded for that fiscal year; activity R44 (SBIR); PI ENGSTROM, PATRIK; recipient as written: PRIMROSE BIO, INC., SAN DIEGO, CA. Enhanced nucleic acid therapeutics: syntheti source ↗
Apr 26, 2023 NIH award 5R44HG010995-03 FY2023: $983,775 awarded for that fiscal year; activity R44 (SBIR); PI ZIELER, HELGE; recipient as written: PRIMROSE BIO, INC., SAN DIEGO, CA. DNA 3.0: Development of a novel, efficient and source ↗
Apr 26, 2022 NIH award 2R44HG010995-02 FY2022: $1,059,968 awarded for that fiscal year; activity R44 (SBIR); PI ZIELER, HELGE; recipient as written: PRIMROSE BIO, INC., SAN DIEGO, CA. DNA 3.0: Development of a novel, efficient an source ↗
Aug 5, 2021 NIH award 5R44GM131548-03 FY2021: $469,286 awarded for that fiscal year; activity R44 (SBIR); PI ZIELER, HELGE; recipient as written: PRIMROSE BIO, INC., SAN DIEGO, CA. Development of superior polymerases for next-ge source ↗
Mar 17, 2021 NIH award 3R43HG010995-01A1S1 FY2021: $52,000 awarded for that fiscal year; activity R43 (SBIR); PI ZIELER, HELGE; recipient as written: PRIMROSE BIO, INC., SAN DIEGO, CA. DNA 3.0: Developing novel enzymes for DNA sy source ↗
Aug 5, 2020 NIH award 2R44GM131548-02 FY2020: $1,152,047 awarded for that fiscal year; activity R44 (SBIR); PI ZIELER, HELGE; recipient as written: PRIMROSE BIO, INC., SAN DIEGO, CA. Development of superior polymerases for next- source ↗
Apr 9, 2020 NIH award 1R43HG010995-01A1 FY2020: $374,524 awarded for that fiscal year; activity R43 (SBIR); PI ZIELER, HELGE; recipient as written: PRIMROSE BIO, INC., SAN DIEGO, CA. DNA 3.0: Developing novel enzymes for DNA syn source ↗
Sep 14, 2018 NIH award 1R43GM131548-01 FY2018: $224,963 awarded for that fiscal year; activity R43 (SBIR); PI ZIELER, HELGE; recipient as written: PRIMROSE BIO, INC., SAN DIEGO, CA. Discovery and development of single-subunit RNA source ↗
Dec 25, 2017 NIH award 1R43GM126828-01 FY2018: $224,952 awarded for that fiscal year; activity R43 (SBIR); PI XU, KAREN D.; recipient as written: PRIMROSE BIO, INC., SAN DIEGO, CA. Synthetic biology E. coli strain development for source ↗